News & Alerts
-
Jul- 2023 -24 July
Current Lawsuits And Settlements In The Healthcare Industry
The healthcare industry is no stranger to legal challenges, and recent reports have shed light on several noteworthy lawsuits and…
Read More » -
22 July
The 10 Most Important Drugs in Human History
The evolution of drug use and its history in human civilization is a journey spanning millennia. Early humans relied on…
Read More » -
22 July
How Much Do Pharmaceutical Companies Spend On Research
Pharmaceutical research refers to the systematic investigation and study of drugs and medications to discover, develop, and evaluate new pharmaceutical…
Read More » -
22 July
Top 10 Best Countries For Pharmaceutical Research
Pharmaceutical research has a rich and diverse history that spans millennia, originating in ancient civilizations where medicinal herbs and natural…
Read More » -
21 July
The 10 Best Hospitals in the World
In today’s rapidly advancing world of medicine, hospitals play a pivotal role in providing cutting-edge healthcare services and advancing medical…
Read More » -
21 July
Novo Nordisk, Eli Lilly, Boehringer Ingelheim Support Medicare Obesity Drug Coverage
Despite the considerable excitement surrounding new and potent obesity medications, the high costs associated with these drugs have made them…
Read More » -
21 July
Nurse Practitioners with Doctorates Challenge California Law on Title Usage
Three California nurse practitioners, all holding Doctor of Nursing Practice (DNP) degrees, have filed a lawsuit against the state of…
Read More » -
21 July
FDA Grants Approval to Vanflyta (Quizartinib) for Acute Myeloid Leukemia with Positive Results
On the 20th of July, 2023, Daiichi Sankyo (TSE: 4568) announced that Vanflyta (quizartinib) has been approved by the U.S. Food and…
Read More » -
21 July
Pfizer’s Plant Destroyed By EF-3 Tornado Was Making 25% of Injectables Used by Hospitals
On July 19, a monstrous EF-3 tornado ripped through Rocky Mount, North Carolina, leaving behind a path of destruction. Among…
Read More » -
20 July
European Medicines Agency Rejects Ipsen’s Palovarotene
Ipsen’s journey with palovarotene, a proposed treatment for the ultra-rare disease fibrodysplasia ossificans progressiva (FOP), has encountered another setback with…
Read More »